{
    "clinical_study": {
        "@rank": "6483", 
        "acronym": "sbrtlungfff", 
        "arm_group": [
            {
                "arm_group_label": "A. 34 Gy in a single fraction", 
                "arm_group_type": "Experimental", 
                "description": "34 Gy by single fraction Risk-adapted radiation dose."
            }, 
            {
                "arm_group_label": "B. 54Gy (18Gy/fr. x 3 fractions)", 
                "arm_group_type": "Experimental", 
                "description": "54Gy administered in 3 fraction of 18 Gy, risk adapted radiation dose"
            }, 
            {
                "arm_group_label": "C. 50Gy (12 x 5 fr.s)", 
                "arm_group_type": "Experimental", 
                "description": "54Gy administered in 5 fraction of 12 Gy, risk adapted radiation dose"
            }, 
            {
                "arm_group_label": "D. 60Gy (7.5Gy x 8fr.)", 
                "arm_group_type": "Experimental", 
                "description": "60 Gy administered in 8 fraction of 7.5 Gy, risk adapted radiation dose"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the safety of Stereotactic Ablative Radiotherapy (SBRT)\n      in selected patients with stage I Non Small Cell Lung Cancer (NSCLC) or metastatic lung\n      cancer to demonstrate the feasibility and risks of using an ablative dose-adapted scheme\n      with FFF beams. Other aims are To evaluate the incidence of acute and late complications; To\n      evaluate tumour response to local radiation therapy by means of CT, PET/TC and MRI and To\n      evaluate the impact of local therapy on overall and disease-free survival."
        }, 
        "brief_title": "Risk Adapted SABR(SABR) in Stage I NSCLC And Lung Metastases", 
        "completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Carcinoma, Non-Small-Cell Lung", 
            "Neoplasm Metastasis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Neoplasm Metastasis", 
                "Neoplasms, Second Primary"
            ]
        }, 
        "detailed_description": {
            "textblock": "The intervention (dose and fractions) depends on topographical parameters: lung disease\n      (primary, peripheral nodes or mediastinal nodes), distance to chest wall, tumour size and\n      distance to main bronchus."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically-confirmed primary lung cancer or lung metastasis from another primary\n             tumour or positive PET/CT suggestive for primary tumour(SUV MAX> 4).\n\n          -  Tumour size < 5 cm in diameter prior to treatment.\n\n          -  Medically inoperable patients as determined by the multidisciplinary thoracic tumour\n             board, or medically operable patients who refuse surgery.\n\n          -  Life expectancy of >12 months.\n\n          -  Criterion for medical inoperability include:\n\n        Overall clinical assessment at the UCLA thoracic tumour board. Reduced Pulmonary Function\n        (FEV1, DLCO, etc) based on one major or two minor criterion as described below: Minor\n        Criteria: Age > 75, FEV1 51- 60% predicted, or FEV1 1-1.2L, DLCO 51%-60% predicted,\n        pulmonary hypertension, poor left ventricular function (EF < 40% or less), resting or\n        exercise arterial pO2 < 55 mmHg, and pCO2 > 45 mmHg.\n\n          -  Age > 18 years.\n\n          -  KPS > 70.\n\n          -  Barthel score >40\n\n          -  Baseline computed tomography scans of the chest, pulmonary test function, and\n             positron emission tomography no more than 2 months before treatment.\n\n          -  If a woman is of childbearing potential, a negative urine or serum pregnancy test\n             must be documented.\n\n          -  Ability to understand and the willingness to sign a written informed consent.\n\n        Exclusion Criteria:\n\n          -  Prior thoracic radiation treatment wich dose contribution can be expected in the new\n             SBRT plan.\n\n          -  More than two lesions per lobe.\n\n          -  Active infections requiring systemic antibiotics.\n\n          -  Age <18 years old.\n\n          -  KPs < 70.\n\n          -  Barthel Total Score < 40."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01823003", 
            "org_study_id": "sbrt_lung_fff2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "A. 34 Gy in a single fraction", 
                "description": "34 Gy in a single fraction in case of Distance to chest wall > 1 cm, tumour size < 2 cm and distance to the main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.", 
                "intervention_name": "34 Gy in a single fraction", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "B. 54Gy (18Gy/fr. x 3 fractions)", 
                "description": "54Gy administered in 3 fractions of 18Gy in case of distance to chest wall > 1 cm, tumour size between 2 and 5 cm and distance to the main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.", 
                "intervention_name": "54Gy 18Gy/fr. x 3 fractions", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "C. 50Gy (12 x 5 fr.s)", 
                "description": "50Gy administered in 5 fractions of 12 Gy for Peripheral Nodes in case of distance to chest wall < 1 cm, tumour size < 5 cm and distance to main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.", 
                "intervention_name": "50Gy (12 x 5 fr.s)", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "D. 60Gy (7.5Gy x 8fr.)", 
                "description": "60 Gy administered in 8 fractions of 7.5 Gy for mediastinal nodes in case of tumour size < 5 cm and distance to the main bronchus < 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.", 
                "intervention_name": "60Gy (7.5Gy x 8fr.)", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Carcinoma, Non-Small-Cell Lung", 
            "Neoplasm Metastasis", 
            "Radiosurgery"
        ], 
        "lastchanged_date": "January 10, 2014", 
        "location": {
            "contact": {
                "email": "anavarro@iconcologia.net", 
                "last_name": "Arturo Navarro-Martin, MD", 
                "phone": "+34.93.260.77.22"
            }, 
            "contact_backup": {
                "email": "vnavarro@iconcologia.net", 
                "last_name": "Valent\u00edn Navarro-P\u00e9rez", 
                "phone": "+34.93.260.78.22"
            }, 
            "facility": {
                "address": {
                    "city": "L'Hospitalet del Llobregat", 
                    "country": "Spain", 
                    "state": "Barcelona", 
                    "zip": "08908"
                }, 
                "name": "Institut Catal\u00e0 d'Oncologia - L'Hospitalet"
            }, 
            "investigator": [
                {
                    "last_name": "Arturo Navarro-Mart\u00edn, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Mar\u00eda Dolores Arn\u00e1iz-Fern\u00e1ndez, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "4", 
        "official_title": "Risk Adapted Free Flattering Filter Based Stereotactic Ablative Radiotherapy (Sabr) in Stage i Nsclc and Lung Metastases", 
        "overall_contact": {
            "email": "anavarro@iconcologia.net", 
            "last_name": "Arturo Navarro-Martin, MD", 
            "phone": "+34.93.260.77.22"
        }, 
        "overall_contact_backup": {
            "email": "vnavarro@iconcologia.net", 
            "last_name": "Valent\u00edn Navarro-P\u00e9rez", 
            "phone": "+34.93.260.78.22"
        }, 
        "overall_official": {
            "affiliation": "Institut Catal\u00e0 d'Oncologia - L'Hospitalet", 
            "last_name": "Arturo Navarro-Martin, md", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients will be follow-up during one year. If patient suffered any toxicity grade 3 or higher during this period it will be classified as having toxicity. Otherwise patient will be classified as not having toxicity.", 
            "measure": "probability of not suffering a grade 3 or higher toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01823003"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate tumour response attending histology with local radiation using imaging such as CT and PET/CT.", 
                "measure": "Tumour response", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }, 
            {
                "description": "To evaluate the frequency of acute and late toxicities.", 
                "measure": "Incidence of acute and late toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "One year"
            }, 
            {
                "description": "To evaluate the impact of local therapy on overall survival.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }, 
            {
                "description": "To evaluate the impact of local therapy on disease-free survival.", 
                "measure": "Disease-free survival", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }, 
            {
                "description": "To evaluate the impact of local therapy on bronchopulmonary (COPD) disease.", 
                "measure": "Effect in brochopulmonary (COPD) disease.", 
                "safety_issue": "Yes", 
                "time_frame": "One year"
            }, 
            {
                "description": "To evaluate the feasibility of this technique in terms of technical complications.", 
                "measure": "Feasibility", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }
        ], 
        "source": "Institut Catal\u00e0 d'Oncologia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institut Catal\u00e0 d'Oncologia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}